<DOC>
	<DOC>NCT01203202</DOC>
	<brief_summary>The purpose of this study is to evaluate whether PED-1 (15mg) and PED-2 (30mg) are tolerable and effective in the treatment of premature ejaculation.</brief_summary>
	<brief_title>Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation</brief_title>
	<detailed_description>This study is to evaluate whether PED-1 and PED2 are tolerable and effective in the treatment of premature ejaculation. The patients will be randomized and allocated to three treatment groups into placebo, PED-1, and PED-2. The creteria for IELT for enrollment will be &gt; or =2 min in the at least 75% of the sexual intercourse. To diagnosis premature ejaculation, the PEDT will be used. The patients ungone drug free baseline line period will take test drugs for 4 weeks.</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<mesh_term>Clomipramine</mesh_term>
	<criteria>Informed consent for subjects and partdners Men 2065 stable monogamous relation at least for 6 mn PEDT more than 9 at least 6 Mn of premature ejaculation Hx IELT of =&lt; 2 min in &gt;= 75% of evaluable events during 4 week secreening period Hx of medical or psychiartric illness erectile dysfunction (&lt;21 IIEF EF domain score) or other forms of sexual dysfunction Partner sexual dysfunction known hypersensitivity to clomipramine and contraindications for clomipramine</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PE</keyword>
	<keyword>IELT</keyword>
	<keyword>DCIT</keyword>
</DOC>